Category list : All-Wales Medicines Strategy Group
Sort by: Newest first Oldest first A-Z Z-A
-
Welsh Labour pledge to create £80m central fund for high cost drugs Subscription
Welsh Labour has pledged to create an £80m central fund to pay for high cost medicines if they retain control of the National Assembly for Wales following the election on 5 May 2016.
-
Welsh audit body recommends managing medicines plan
The government, the NHS and health bodies should revise the indicators used to compare how different prescribers and organisations use medicines, says a report by the Welsh Audit Office.
-
Treatment fund launched in Wales for newly approved drugs
An £80m new treatment fund to pay for high-cost drugs approved for use on the NHS in Wales has been launched.
-
Three-year PrEP pilot begins in Wales
A trial has begun in Wales to assess the use of the antiretroviral combination treatment emtricitabine/tenofovir disoproxil (marketed as Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection.
-
Revlar Ellipta approved for NHS use in Wales
Inhaled fluticasone furoate and vilanterol (Relvar Ellipta) has been approved for use in NHS Wales by the All-Wales Medicines Strategy Group (AWMSG). it is recommended as an option for symptomatic treatment of adults with chronic obstructive pulmonary disease.
-
Restrictions on prescribing OTC treatments rejected in Wales Subscription
Proposals to restrict the prescribing of medicines and other treatments that are available over the counter will not go ahead in Wales.
-
New constipation drug gets a lukewarm response from DTB
Little published data on lubiprostone made it difficult to assess its efficacy, says the DTB
-
June 2015 AWMSG approvals Subscription
Adalimumab (Humira; AbbVie) can be prescribed in NHS Wales to treat active, enthesitis-related arthritis in patients aged six years and older, following its use being approved by the All Wales Medicines Strategy Group (AWMSG). The group has not recommended dapagliflozin (Forxgia; Bristol-Myers Squibb) as monotherapy for type 2 diabetes or aflibercept (Zaltrap; Sanofi) for metastatic colorectal cancer (in combination with irinotecan, ...
-
July 2015: AWMSG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstructive pulmonary disease, and Adcetris (brentuximab; Takeda) for adults with relapsed or refractory CD30+ Hodgkin lymphoma who have undergone an autologous stem cell transplant or following at least two other therapies. The drug is not recommended for treating systemic anaplastic large cell ...
-
January 2016: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...
Show 10 per page20 per page50 per page
